Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 101–200 of 769
Collins, M. A., Yan, W., Sebolt–Leopold, J. S., & Pasca di Magliano, M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.052 · Cited by 133
Self-citationGEMMs as preclinical models for testing pancreatic cancer therapies
Gopinathan, A., Morton, J. P., Jodrell, D. I., & Sansom, O. J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021055 · Cited by 149
Chronic pancreatitis: A path to pancreatic cancer
Pinho, A. V., Chantrill, L. A., & Rooman, I. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.015 · Cited by 150
Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages
Kemp, S. B., Steele, N. G., Carpenter, E. S., Donahue, K. L., Bushnell, G. G., Morris, A. H., The, S., Orbach, S. M., Sirihorachai, V. R., Nwosu, Z. C., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202000935 · Cited by 159
“C57/BL6J mice (stock number #000664; Jackson Laboratory), KPC (Hingorani et al, 2005), iKras* (Collins et al, 2012a), and iKras* p53* (Collins et al, 2012b) mice were used for mouse experiments.”
MethodSelf-citationHu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Molecular subtypes in cancers of the gastrointestinal tract
Bijlsma, M. F., Sadanandam, A., Tan, P. B. O., & Vermeulen, L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.33 · Cited by 150
Therapeutic options for the management of pancreatic cancer
Rossi, M. L., Rehman, A. A., & Gondi, C. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11142 · Cited by 142
Coffman, L. G., Choi, Y.-J., McLean, K., Allen, B. L., di Magliano, M. P., & Buckanovich, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.6870 · Cited by 127
“To confirm HH activity in normal ovaries and ovarian tumors we used a Gli1lacZ reporter mouse [24, 25].”
MethodKumar, S., Schoonderwoerd, M. J. A., Kroonen, J. S., de Graaf, I. J., Sluijter, M., Ruano, D., González‐Prieto, R., Vries, M. V., Rip, J., Arens, R., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324834 · Cited by 145
ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation
Dumartin, L., Alrawashdeh, W., Trabulo, S. M. D., Radon, T. P., Steiger, K., Feakins, R. M., di Magliano, M. P., Heeschen, C., Esposito, I., Lemoine, N. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.459 · Cited by 138
Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies
Liu, L., Kshirsagar, P. G., Gautam, S. K., Gulati, M., Wafa, E. I., Christiansen, J. C., White, B. M., Mallapragada, S. K., Wannemuehler, M. J., Kumar, S., et al. (2022) · Theranostics · doi:10.7150/thno.64805 · Cited by 124
“A Japanese study analyzed LN metastasis in 429 PDAC patients and identified high incidence in advanced PDACs [249].”
BackgroundPancreatic cancer and its stroma: A conspiracy theory
Xu, Z., Pothula, S. P., Wilson, J. S., & Apte, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11216 · Cited by 141
Deciphering the role of stroma in pancreatic cancer
Waghray, M., Yalamanchili, M., Magliano, M. P. D., & Simeone, D. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328363affe · Cited by 124
“The recently described iKras mice [47] express KrasG12D in a tissue-specific manner.”
BackgroundPancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
Pelosi, E., Castelli, G., & Testa, U. (2017) · Biomedicines · doi:10.3390/biomedicines5040065 · Cited by 147
“The results of these studies clearly showed that oncogenic KRAS is required for both the initiation and the maintenance of pancreatic cancer in mice [86].”
BackgroundInfluentialKRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura, S. F., Khan, H. Y., & Azmi, A. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013902 · Cited by 125
Baumgart, S., Chen, N., Siveke, J. T., König, A. O., Zhang, J., Singh, S. K., Wolf, E., Bartkuhn, M., Esposito, I., Heßmann, E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0593 · Cited by 123
“novel drugs in prevention and therapy (4,14,15).”
Stromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 120
Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma
Garcia, P. E., Adoumie, M., Kim, E. C., Zhang, Y., Scales, M. K., El-Tawil, Y. S., Shaikh, A. Z., Wen, H.-J., Bednar, F., Allen, B. L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.05.004 · Cited by 110
“Immunohistochemistry and Immunofluorescence All immunohistochemical and immunofluorescent stains were performed as previously described.(78) Primary antibodies used were as follows: YFP (1:200; Abcam, Cambridge, MA), PDGFRb (1:100; Abcam), cytokeratin 19 (1:50; Iowa Developmental Hybridoma Bank, Iowa City, IA), aSMA (…”
MethodSelf-citationTarget c-Myc to treat pancreatic cancer
Ala, M. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2017223 · Cited by 128
“Mutant KRAS activates several signaling pathways in the pancreas to reprogram pancreatic acini into pancreatic cancer.(65) In addition to PI3K/AKT/mTOR and WNT/β-catenin, Mutant”
BackgroundCurrent Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 123
Oncogenes and tumor suppressor genes: functions and roles in cancers
Dakal, T. C., Dhabhai, B., Pant, A., Moar, K., Chaudhary, K., Yadav, V., Ranga, V., Sharma, N. K., Kumar, A., Maurya, P. K., et al. (2024) · MedComm · doi:10.1002/mco2.582 · Cited by 171
Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
Biology and Clinical Applications of Pancreatic Cancer Stem Cells
Abel, E. V., & Simeone, D. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.072 · Cited by 123
Functions and mechanisms of microRNA-31 in human cancers
Yu, T., Ma, P., Wu, D., Shu, Y., & Gao, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.09.132 · Cited by 116
Bourgot, I., Primac, I., Louis, T., Noël, A., & Maquoi, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01488 · Cited by 113
“During cancer progression, fibroblast activation and expansion is induced (Figure 1), such that low-grade premalignant lesions are already surrounded by areas of fibrosis (91).”
BackgroundIL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation
Zhuang, Z., Ju, H.-Q., Aguilar, M., Gocho, T., Li, H., Iida, T., Lee, H., Fan, X., Zhou, H., Ling, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3382 · Cited by 113
Kras as a key oncogene and therapeutic target in pancreatic cancer
Collins, M. A., & di Magliano, M. P. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00407 · Cited by 132
Self-citationMicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential
Rawat, M., Kadian, K., Gupta, Y. A., Kumar, A., Chain, P. S. G., Kovbasnjuk, O. N., Kumar, S., & Parasher, G. (2019) · Genes · doi:10.3390/genes10100752 · Cited by 129
“Recent studies have shown that numerous miRNAs negatively target the KRAS pathway by inhibiting the translation of, or by degrading the KRAS mRNA transcripts [89].”
BackgroundSchlitter, A. M., Segler, A., Steiger, K., Michalski, C. W., Jäger, C., Konukiewitz, B., Pfarr, N., Endris, V., Bettstetter, M., Kong, B., et al. (2017) · Scientific Reports · doi:10.1038/srep41064 · Cited by 112
Tobacco and alcohol as risk factors for pancreatic cancer
Korc, M., Jeon, C. Y., Edderkaoui, M., Pandol, S. J., & Petrov, M. S. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.001 · Cited by 116
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Kunk, P. R., Bauer, T. W., Slingluff, C. L., & Rahma, O. E. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0119-z · Cited by 110
“In pancreatic cancer, it has been suggested that low concentration of mast cells in the PTME correlates with increased survival [28] while increased concentration is associated with increased lymph node metastases based on retrospective analyses in small subsets of patients [29].”
BackgroundInfluentialEpithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice
Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0016-t · Cited by 102
“However, the synergy of oncogenic Kras expression and the induction of inflammation (namely chronic or acute pancreatitis) induce rapid and extensive PanIN formation (17, 19).”
InfluentialSelf-citationLi, Y., He, Y., Peng, J., Su, Z., Li, Z., Zhang, B., Ma, J., Zhuo, M., Zou, D., Liu, X., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00134-z · Cited by 113
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
“73 TGF-b exists predominantly in a latent form associated with latency-associated peptide (LAP) and bound to the extracellular matrix (ECM) protein fibrillin or docked to the surface of cell types including regulatory T cells (Tregs), 74 platelets, and cancer cells through the transmembrane protein…”
BackgroundOzkan-Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz-Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 106
“Given the >95% KRAS mutation frequency in PDAC and substantial experimental evidence that KRAS is essential for PDAC maintenance (Collins et al., 2012; Ying et al., 2012), KRAS is the most attractive target for therapeutic intervention in this disease (Waters and Der, 2018).”
BackgroundGLI1: A Therapeutic Target for Cancer
Avery, J. T., Zhang, R., & Boohaker, R. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.673154 · Cited by 115
Li, X., Deng, S.-J., Zhu, S., Jin, Y., Cui, S.-P., Chen, J.-Y., Xiang, C., Li, Q.-Y., He, C., Zhao, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6830 · Cited by 107
“Except for that research reveals that mutation of KRAS is required in the initiation and maintenance of pancreatic cancer [22], some results further imply that the KRAS overexpression is also valuable to be uncovered for tumorigenesis.”
BackgroundCostanza, B., Rademaker, G., Tiamiou, A., Tullio, P. D., Leenders, J., Blomme, A., Bellier, J., Bianchi, E., Turtoï, A., Delvenne, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32247 · Cited by 112
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 122
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 130
“(a) There are germline and somatic mutations, such as KRAS, p53, p16 and SMAD4,that predispose to PDAC [129–149]; (b) KRAS mutation and activation represent a critical factor in initiation [150,151]; (c) Pancreatica cancer originates from acinar and ductal cells [152]; (d) Progression from normal cells into invasive d…”
BackgroundChen, N., Singh, G., König, A. O., Liou, G., Störz, P., Zhang, J., Regul, L., Nagarajan, S., Kühnemuth, B., Johnsen, S. A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.033 · Cited by 105
ROS and TGFβ: from pancreatic tumour growth to metastasis
Chang, C., & Pauklin, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01960-4 · Cited by 110
“Ras-ERK pathway mediates not only PDAC initiation, but also tumour growth and maintenance [32].”
BackgroundCancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Polireddy, K., & Chen, Q. (2016) · Journal of Cancer · doi:10.7150/jca.14922 · Cited by 119
“Continuous K-Ras signaling is required for pancreatic cancer cells for sustained proliferation and survival (8).”
BackgroundCD44 Regulates Pancreatic Cancer Invasion through MT1-MMP
Jiang, W., Zhang, Y., Kane, K. T., Collins, M. A., Simeone, D. M., di Magliano, M. P., & Nguyen, K. T. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0076 · Cited by 102
“Western blot analysis was performed as previously described (11).”
MethodSelf-citationExtrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91
“widespread early PanIN lesions at 3 weeks after pancreatitis induced by caerulein, and withdrawal of DOX (Kras OFF) at this stage leads to PanIN regression and tissue repair.(25) Thus, epithelial oncogenic Kras is required to maintain acinar transdifferentiation.”
BackgroundMethodResultInfluentialSelf-citationJi, S., Qin, Y., Liang, C., Huang, R., Shi, S., Liu, J., Jin, K., Liang, D., Xu, W., Zhang, B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2380 · Cited by 96
“Elevated oncogenic KRAS activity stimulates many downstream signaling pathways (36-37).”
BackgroundRisk factors for pancreatic cancer: underlying mechanisms and potential targets
Kolodecik, T., Shugrue, C., Ashat, M., & Thrower, E. C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00415 · Cited by 93
“In mouse models, inactivation of oncogenic Kras results in tumor regression and the animals remain healthy over time with no signs of relapse (Collins et al., 2012a,b; Ying et al., 2012).”
BackgroundSomatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
“In transgenic mice, the pancreas-specific and reversible expression of inducible KRAS G12D mutant was shown not only to initiate neoplastic lesions but was also involved in tumor maintenance [26].”
Dosage-Dependent Regulation of Pancreatic Cancer Growth and Angiogenesis by Hedgehog Signaling
Mathew, E., Zhang, Y., Holtz, A. M., Kane, K. T., Song, J. Y., Allen, B. L., & Pasca di Magliano, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.010 · Cited by 93
“, 2005) and iKras (Collins et al., 2012) pancreatic cancer models.”
BackgroundMethodSelf-citationMiglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 98
Pathogenesis and Treatment of Pancreatic Cancer Related Pain
Lohse, I., & Brothers, S. P. (2020) · Anticancer Research · doi:10.21873/anticanres.14133 · Cited by 110
Baer, J. M., Zuo, C., Kang, L., de la Lastra, A. A., Borcherding, N. C., Knolhoff, B. L., Bogner, S. J., Zhu, Y., Yang, L., Poursine‐Laurent, J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-023-01579-x · Cited by 110
Zhang, A. M. Y., Xia, Y. H., Lin, J. S. H., Chu, K., Wang, W. C. K., Ruiter, T. J. J., Yang, J. C. C., Chen, N., Chhuor, J., Patil, S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.003 · Cited by 112
Reproducible Automated Phosphopeptide Enrichment Using Magnetic TiO2 and Ti-IMAC
Tape, C. J., Worboys, J. D., Sinclair, J., Gourlay, R., Vogt, J., McMahon, K. M., Trost, M., Lauffenburger, D. A., Lamont, D. J., & Jørgensen, C. (2014) · Analytical Chemistry · doi:10.1021/ac5025842 · Cited by 90
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“…KRAS mutations depend on sustained expression of the oncogene for cell proliferation and viability (Podsypanina et al. 2008; Singh et al. 2009; Collins et al. 2012; Ying et al. 2012; Kapoor et al. 2014; Shao et al. 2014; Hayes et al. 2016), making oncogenic KRAS a high-priority therapeutic…”
BackgroundDaraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Regulation of Cellular Identity in Cancer
Roy, N., & Hebrok, M. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.12.001 · Cited by 104
“Using a mouse model that permitted pancreas-specific, temporally regulated and reversible expression of mutant Kras, Magliano and colleagues showed that oncogenic Kras reversibly altered normal epithelial differentiation following tissue damage (Collins et al., 2012).”
BackgroundMARSTRAND-DAUCE, L., Lorenzo, D., Chassac, A., Nicole, P., Couvelard, A., & Haumaître, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129946 · Cited by 119
“However, in the case of persistent aberrant growth factor signaling or concomitant oncogenic activation such as the KrasG12D activating mutation, the metaplastic cells cannot revert to a differentiated state, leading to irreversible ADM, facilitating the onset of PanIN and PDAC development.”
BackgroundAutophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation
Yang, S., Imamura, Y., Jenkins, R. W., Cañadas, I., Kitajima, S., Aref, A., Brannon, A., Oki, E., Castoreno, A., Zhu, Z., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0235 · Cited by 89
“Acinar-to-ductal metaplasia (ADM) and PanIN lesions in mice were quantified by grade in a blinded manner (28).”
BackgroundMethodJiang, X., Seo, Y. D., Chang, J. H., Coveler, A. L., Nouri-Nigjeh, E., Pan, S., Jalikis, F. G., Yeung, R. S. W., Crispe, I. N., & Pillarisetty, V. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1333210 · Cited by 97
“This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is…”
BackgroundInfluentialTargeted Therapies for Pancreatic Cancer and Hurdles Ahead
Aslan, M., Shahbazi, R., Ulubayram, K., & Özpolat, B. (2018) · Anticancer Research · doi:10.21873/anticanres.13026 · Cited by 96
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 104
“To have a constant proliferation and survival, pancreatic cancer cells need continuous K-Ras signaling [18].”
BackgroundLuo, Y., Yang, Y., Liu, M., Wang, D., Wang, F., Bi, Y., Ji, J., Li, S., Liu, Y., Chen, R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.07.030 · Cited by 87
Niu, N., Lu, P., Yang, Y., He, R., Zhang, L., Shi, J., Wu, J., Yang, M., Zhang, Z.-G., Wang, L.-W., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318362 · Cited by 86
KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops
Eibl, G., & Rozengurt, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.007 · Cited by 85
“During early carcinogenesis inactivation of KRAS led to re-differentiation of PanINs to normal pancreatic lineages (acinar cells) or apoptosis, while inactivation of KRAS in advanced disease led to tumor regression [26,27].”
BackgroundEmerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Neeße, A., Gress, T. M., Tuveson, D. A., Michl, P., & Krug, S. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38111 · Cited by 96
“…expression of oncogenic K-ras G12D indicates that abrogation of mutant K-ras in established tumors led to dramatic tumor shrinkage and depletion of the surrounding stroma after only a few days, 55,56 further highlighting the key function of mutant K-ras in shaping tumor biology in PDA.”
Bijlsma, M. F., & van Laarhoven, H. W. M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9541-1 · Cited by 89
Inflammation as a driver and vulnerability of KRAS mediated oncogenesis
Kitajima, S., Thummalapalli, R., & Barbie, D. A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.009 · Cited by 84
“These results have spurred several clinical trials combining a variety of different MEK inhibitors with anti-PD1 or anti-PD-L1 inhibitors across different tumor types, including KRAS mutant LUAC, PDAC, and CRC.”
BackgroundInfluentialSOX9 regulates ERBB signalling in pancreatic cancer development
Grimont, A., Pinho, A. V., Cowley, M. J., Augereau, C., Mawson, A., Giry-Laterrière, M., Van den Steen, G., Waddell, N., Pajic, M., Sempoux, C., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307075 · Cited by 84
p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis
Wang, F., Qi, X.-M., Wertz, R., Mortensen, M., Hagen, C. E., Evans, J., Sheinin, Y. M., James, M. A., Liu, P., Tsai, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3281 · Cited by 84
Perusina Lanfranca, M., Zhang, Y., Girgis, A., Kasselman, S., Lazarus, J., Kryczek, I., Delrosario, L., Rhim, A., Koneva, L., Sartor, M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.010 · Cited by 81
Self-citationMurakami, S., Nemazanyy, I., White, S. M., Chen, H., Nguyen, C. D. K., Graham, G. T., Saur, D., Pende, M., & Yi, C. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.07.022 · Cited by 83
“We show that Yap ablation, resembling previously reported Kras silencing, causes metabolic crisis and regression of PDAC tumors, which is followed by extensive tissue re-modeling cumulating in partial recovery of acinar parenchyma (Collins et al., 2012; Ying et al., 2012).”
BackgroundMcIntyre, C. A., Grimont, A., Park, J., Meng, Y., Sisso, W. J., Seier, K. P., Jang, G. H., Walch, H. S., Aveson, V. G., Falvo, D. J., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.002 · Cited by 97
Cheng, H., Fan, K., Luo, G., Fan, Z., Yang, C., Huang, Q., Jin, K., Xu, J., Yu, X., & Liu, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.013 · Cited by 83
Jia, X., Xu, W., Ye, Z., Wang, Y., Dong, Q., Wang, E., Li, D., & Wang, J. (2020) · Small · doi:10.1002/smll.202003707 · Cited by 82
Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer
Lin, W.-C., Rajbhandari, N., Liu, C., Sakamoto, K., Zhang, Q., Triplett, A. A., Batra, S. K., Opavský, R., Felsher, D. W., DiMaio, D. J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2067 · Cited by 84
“None of these tumor cell samples carried mutations in codons 12, 13, and 61 of Kras (not shown) and, therefore, a gain-of-function of Kras does not appear to be the underlying mechanism for the survival of a small subset of residual cancer cells following ablationof c-Myc.”
InfluentialRavichandran, M., Hu, J., Cai, C., Ward, N. P., Venida, A., Foakes, C., Kuljanin, M., Yang, A., Hennessey, C. J., Yang, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0044 · Cited by 80
Liang, C., Shi, S., Liu, M., Qin, Y., Meng, Q., Hua, J., Ji, S., Zhang, Y., Yang, J., Xu, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1968 · Cited by 81
Self-citationOncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.079 · Cited by 80
Cancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M., & Cameron, A. J. M. (2022) · The Journal of Pathology · doi:10.1002/path.5926 · Cited by 91
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
“Distinct signaling pathways in KRAS-driven adenocarcinomas Oncogenic K-Ras signaling in PDAC is complex and dynamic (44-46).”
BackgroundGarcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77
“To address these issues, several laboratories developed tetracycline-inducible expression of mutant KRASG12D allele in pancreatic tissues, and administration of doxycycline initiates KRASG12D tumorigenesis that develop into PDAC [56,57].”
BackgroundGenetic Progression of Pancreatic Cancer
Cowan, R. W., & Maitra, A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000011 · Cited by 77
“In addition to activating the traditional targets of KRAS signaling, such as the phosphoinositide 3-kinase pathway and the RAFYmitogen-activated protein kinase (MAPK) pathway that govern such things as proliferation, cell division, survival, and gene expression,(51) oncogenic Kras also stimulates the proliferation of…”
BackgroundPathological and Molecular Evaluation of Pancreatic Neoplasms
Rishi, A., Goggins, M., Wood, L. D., & Hruban, R. H. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.004 · Cited by 90
Yao, Y., Zhou, L., Liao, W., Chen, H., Du, Z., Shao, C., Wang, P., & Ding, K. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2018.10.008 · Cited by 83
Song, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 89
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma
Tu, B., Yao, J., Ferri-Borgogno, S., Zhao, J., Chen, S., Wang, Q., Yan, L., Zhou, X., Zhu, C., Bang, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130811 · Cited by 75
Malik, R., Luong, T., Cao, X., Han, B., Shah, N., Franco-Barraza, J., Han, L., Shenoy, V. B., Lelkes, P. I., & Cukierman, E. (2019) · Matrix Biology · doi:10.1016/j.matbio.2018.11.001 · Cited by 74
“Along with stromal alterations, over 90% of all PDACs encompass Kirsten retrovirus associated to sarcoma (KRAS) mutations [7–9], which are evident during early phases of PDAC manifestation [10] and essential for both tumor initiation and progression [11, 12].”
BackgroundmTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer
Driscoll, D. R., Karim, S. A., Sano, M., Gay, D. M., Jacob, W., Yu, J., Mizukami, Y., Gopinathan, A., Jodrell, D. I., Evans, T. R. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0810 · Cited by 74
“Indeed, inducible mouse models have demonstrated that pancreatic tumors retain dependence on activated KRAS signaling (44,45).”
BackgroundProgress in the Treatment of Metastatic Pancreatic Cancer and the Search for Next Opportunities
Ko, A. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7625 · Cited by 78
The Emerging Role of Vitamin B6 in Inflammation and Carcinogenesis
Bird, R. P. (2018) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2017.11.004 · Cited by 83
“Tumor microenviron- ment is responsible for cancer-associated inflammation and for epithelial to mesenchymal transition, angiogenesis, and metastasis by interacting with the tumor cells (Collins et al., 2012).”
BackgroundEstrada‐Bernal, A., Chatterjee, M., Haque, S. J., Yang, L., Morgan, M. A., Kotian, S., Morrell, D., Chakravarti, A., & Williams, T. M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1104437 · Cited by 76
“the growth, survival and migration of pancreatic cancer cells.(8,9) The oncogenic mutant KRAS also activates the PI3K-AKT/ mTOR pathway that plays many critical roles in tumorigenesis.”
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
“6 essential actor to their survival and progress although a slow evolution that requires additional genetic events such as Trp53, Ink4a/ARF, Smad4 tumor suppressor mutations to form invasive adenocarcinoma (25-29).”
BackgroundObesity and Pancreatic Cancer: Insight into Mechanisms
Eibl, G., & Rozengurt, E. (2021) · Cancers · doi:10.3390/cancers13205067 · Cited by 80
Kong, B., Qia, C., Erkan, M., Kleeff, J. H., & Michalski, C. W. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00246 · Cited by 76
“Recent epidemiological and animal studies suggest that the supplementation of dietary antioxidants (e.g., vitamins C and E) decreases cancer risk, implying that increased reactive oxygen species (ROS) may play a role in pancreatic carcinogenesis.”
BackgroundCrawford, H. C., di Magliano, M. P., & Banerjee, S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.042 · Cited by 77
Paligenosis: Cellular Remodeling During Tissue Repair
Brown, J. W., Cho, C. J., & Mills, J. C. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-061121-035954 · Cited by 75
Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach
Cosquer, G. L., Maulat, C., Bournet, B., Cordelier, P., Buscail, É., & Buscail, L. (2023) · Cancers · doi:10.3390/cancers15030761 · Cited by 80
“cells only following treatment with cerulein [23].”
BackgroundOral bacteria accelerate pancreatic cancer development in mice
Saba, E., Farhat, M., Daoud, A., Khashan, A., Forkush, E., Menahem, N. H., Makkawi, H., Pandi, K., Angabo, S., Kawasaki, H., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-330941 · Cited by 82
“56 57 Similarly, autopsy studies have shown that most adults have PanINs containing cells with mutations in KRAS without developing invasive disease, further supporting the notion that oncogenic KRAS does not induce PDAC efficiently.”
Background
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.